|Harren Jhoti (CEO)
Martin Buckland (CBO)
Astex Therapeutics was a biotechnology company focused on the discovery and development of drugs in oncology and other areas. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.
The company's research efforts focus on utilization of a proprietary "drug discovery engine" dubbed Pyramid. Astex has also solved the structure of two key cytochrome P450 isoenzymes involved in drug metabolism, 2C9 & 3A4, which the company hopes will help in optimizing the pharmacokinetic properties and safety of their lead compounds.
Astex Therapeutic's first drug candidate, a cell cycle inhibitor, entered Phase I clinical trials in 2005. Since that time they have created eight drugs that have progressed into the clinical stage of development.
- Tom Blundell: Director Archived January 1, 2015, at the Wayback Machine. on OpenCorporates
- Congreve, M; Murray, C. W.; Blundell, T. L. (2005). "Structural biology and drug discovery". Drug Discovery Today. 10 (13): 895–907. PMID 15993809. doi:10.1016/S1359-6446(05)03484-7.
- Williams, P. A.; Cosme, J; Vinkovic, D. M.; Ward, A; Angove, H. C.; Day, P. J.; Vonrhein, C; Tickle, I. J.; Jhoti, H (2004). "Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone". Science. 305 (5684): 683–6. PMID 15256616. doi:10.1126/science.1099736.
- Repasky, M. P.; Murphy, R. B.; Banks, J. L.; Greenwood, J. R.; Tubert-Brohman, I; Bhat, S; Friesner, R. A. (2012). "Docking performance of the glide program as evaluated on the Astex and DUD datasets: A complete set of glide SP results and selected results for a new scoring function integrating Water Map and glide". Journal of Computer-Aided Molecular Design. 26 (6): 787–99. PMID 22576241. doi:10.1007/s10822-012-9575-9.
- Novikov, F. N.; Stroylov, V. S.; Zeifman, A. A.; Stroganov, O. V.; Kulkov, V; Chilov, G. G. (2012). "Lead Finder docking and virtual screening evaluation with Astex and DUD test sets". Journal of Computer-Aided Molecular Design. 26 (6): 725–35. PMID 22569592. doi:10.1007/s10822-012-9549-y.
- Wolfson, W (2006). "Fragmentary solutions. Astex therapeutics puts the pieces together". Chemistry & Biology. 13 (8): 799–801. PMID 16931326. doi:10.1016/j.chembiol.2006.08.003.
- Mountain, V (2003). "Astex, Structural Genomix, and Syrrx. I can see clearly now: Structural biology and drug discovery". Chemistry & Biology. 10 (2): 95–8. PMID 12618177. doi:10.1016/s1074-5521(03)00030-9.
- Carr, R. A.; Congreve, M; Murray, C. W.; Rees, D. C. (2005). "Fragment-based lead discovery: Leads by design". Drug Discovery Today. 10 (14): 987–92. PMID 16023057. doi:10.1016/S1359-6446(05)03511-7.
- Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
- Supergen Press Release April 6, 2011 "http://investor.astx.com/releasedetail.cfm?ReleaseID=601567[permanent dead link]"
- Astex Technology: Pioneering Fragment-based Lead Discovery